GSK - GlaxoSmithKline's Nucala Success And Other News: The Good Bad And Ugly Of Biopharma
GlaxoSmithKline's Nucala Achieves Co-Primary Endpoints
GlaxoSmithKline (GSK) announced that its drug candidate Nucala met co-primary endpoints for the pivotal SYNAPSE study. The trial was designed to assess the efficacy of this asthma drug in treating patients with nasal polyps associated with chronic rhinosinusitis. This late stage trial combined the drug with standard of care. The company intends to use this data for supporting its regulatory submissions later this year.
GlaxoSmithKline stated that this is the first time an anti-IL5 biologic has produced positive results in Phase 3 trials pertaining chronic rhinosinusitis. The co-primary